Article: [New Complement Therapeutics in Complement-Related Diseases].
Brain and nerve = Shinkei kenkyu no shinpo
2019 Volume 71, Issue 6, Page(s) 555–564
Abstract: The complement was named after "a complement", a protein molecule that supports an antibody. It was considered previously that the complement mainly participates in protecting against microbial infections. But later, as research on biological functions ... ...
Abstract | The complement was named after "a complement", a protein molecule that supports an antibody. It was considered previously that the complement mainly participates in protecting against microbial infections. But later, as research on biological functions in complement activation advanced drastically, it was elucidated that the complement could be involved in the onset of various diseases. In 2007, eculizumab (ECZ), an anti-C5 (complement factor 5) monoclonal antibody, was approved as a drug for paroxysmal nocturnal hemoglobinuria (PNH) in the United States. In Japan, ECZ was approved for PNH and atypical hemolytic uremic syndrome (aHUS) in 2010 and 2013, respectively. The success of ECZ created an opportunity for drug companies to develop new therapeutics targeting the complement system; development of complement therapeutics is now a major venture of pharmaceutical companies worldwide. Here, I will provide an outline of the approved complement therapeutics and those that are in development and clinical trial phase currently. |
---|---|
MeSH term(s) | Antibodies, Monoclonal, Humanized/therapeutic use ; Atypical Hemolytic Uremic Syndrome/drug therapy ; Clinical Trials as Topic ; Complement C5/antagonists & inhibitors ; Complement Inactivating Agents/therapeutic use ; Complement System Proteins ; Hemoglobinuria, Paroxysmal/drug therapy ; Humans ; Japan |
Chemical Substances | Antibodies, Monoclonal, Humanized ; Complement C5 ; Complement Inactivating Agents ; Complement System Proteins (9007-36-7) ; eculizumab (A3ULP0F556) |
Language | Japanese |
Publishing date | 2019-06-06 |
Publishing country | Japan |
Document type | Journal Article ; Review |
ZDB-ID | 390389-8 |
ISSN | 1344-8129 ; 1881-6096 ; 0006-8969 |
ISSN (online) | 1344-8129 |
ISSN | 1881-6096 ; 0006-8969 |
DOI | 10.11477/mf.1416201316 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 398: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.